Perioperative suppression of platelet adherence to small-diameter polytetrafluoroethylene (PTFE) grafts.
The perioperative effect of platelet antagonists on small-diameter polytetrafluoroethylene (PTFE) grafts was evaluated in forty-six New Zealand white male rabbits receiving either dipyridamole (DPM) 100 mg/kg/day (n = 10; group 1), aspirin (ASA) 10 mg/kg/day (n = 10; group 2), a combination of ASA 10 mg/kg/day and DPM 10 mg/kg/day (n = 9; group 3) or 100 mg/kg/day (n = 10; group 4), or placebo (n = 7) as single daily doses. All regimens began 72 hr prior to insertion of a 20 x 3-mm internal diameter PTFE interposition aortic graft. Autologous indium-111 labeled platelets were injected immediately after implantation. Graft and an equivalent segment of aorta were harvested after 48 hr. Graft platelet adherence index (GPAI) was calculated as the graft:reference aorta ratio of emissions. The GPAI in the control group was 238 +/- 46 (mean +/- SD). Single regimen antiplatelet agents in groups 1 and 2 reduced mean GPAI to 47 +/- 38 and 40 +/- 12, respectively. The combination regimen in group 3 lowered mean GPAI to 43 +/- 8 and in group 4 to 21 +/- 7. Platelet uptake in PTFE grafts at 48 hr is significantly lowered to 8.8 to 19.7% of control by perioperative antiplatelet agents given as a single daily oral dose (P less than 0.001). ASA alone and DPM alone provided similar suppression of platelet uptake, but combination ASA + low dose or high dose DPM gave significantly greater (P less than 0.001) suppression of early platelet deposition than the single agent regimens. These results support perioperative administration of combination oral antiplatelet agents as adjunctive therapy in small diameter prosthetic graft implantation.
Fujitani
R M
RM
Department of Surgery, Harbor-UCLA Medical Center, Torrance 90509.
Nordestgaard
A G
AG
Marcus
C S
CS
Wilson
S E
SE
D000818:Animals; D001011:Aorta / Q000502:physiology; D001241:Aspirin / Q000097:blood / Q000627:therapeutic use*; D001807:Blood Vessel Prosthesis; D004176:Dipyridamole / Q000097:blood / Q000627:therapeutic use*; D004338:Drug Combinations; D010973:Platelet Adhesiveness / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011138:Polytetrafluoroethylene; D011300:Preoperative Care; D012039:Regional Blood Flow; D013929:Thromboxane B2 / Q000097:blood; D014654:Vascular Patency
D004338:Drug Combinations; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D004176:Dipyridamole; D011138:Polytetrafluoroethylene; D001241:Aspirin